Tag: nucleic acid and gene therapies in neuromuscular disorders market analysis

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Value Analysis: What Growth Is Expected Over The Forecast Period?

The market for nucleic acid and gene therapies targeting neuromuscular disorders has experienced robust expansion lately, with projections indicating continued growth from $7.5 billion in 2025 to $8.22 billion in 2026, reflecting a compound annual growth rate of 9.7%. Historically, this sector’s advancement was influenced by factors such as the scarcity of effective treatments for neuromuscular disorders (NMDs), a nascent understanding of gene therapy’s potential, substantial expenses associated with gene therapy research and creation, a deficit of dedicated medical facilities, and protracted regulatory authorization processes.

The market for nucleic acid and gene therapies targeting neuromuscular disorders is poised for substantial expansion, projected to reach $11.76 billion by 2030 with a compound annual growth rate of 9.4%. This anticipated surge is fueled by several key drivers, including significant progress in adeno-associated virus and postnatal gene therapy technologies, escalating research and development expenditures dedicated to neuromuscular disorders (NMDs), and an expanding network of healthcare facilities, such as hospitals and specialized clinics, that are increasingly providing these advanced therapies. Furthermore, the rising incidence of neuromuscular conditions, coupled with heightened patient awareness and the impact of advocacy efforts, are also contributing factors to this growth trajectory. Key developments shaping the market over the forecast period involve a greater embrace of gene therapy methodologies, a heightened focus on the development of nucleic acid-based treatments, a concentrated effort on addressing rare neuromuscular conditions, increased financial backing for personalized medicine strategies, and the more widespread incorporation of sophisticated diagnostic and monitoring technologies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21233&type=smp

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Growth Factors: Which Forces Are Supporting Market Expansion?

The rising incidence of genetic conditions is anticipated to stimulate advancements in the market for nucleic acid and gene therapies targeting neuromuscular disorders. Genetic disorders, characterized by alterations in an individual’s genetic makeup, whether inherited or acquired through mutations, are becoming more widespread due to a combination of genetic predispositions, environmental factors, evolving lifestyles, and enhanced diagnostic techniques. Nucleic acid and gene therapies offer a promising approach to addressing these disorders by rectifying or substituting faulty genes within the neuromuscular system, thereby restoring proper function. A pertinent example is Spinal Muscular Atrophy (SMA), a neuromuscular disorder affecting an estimated 9,000 to 9,500 individuals in the United States as of May 2024, with Type 2 SMA accounting for 37% of these cases. This condition occurs with an approximate frequency of 1 in every 15,000 live births, underscoring the growing impact of genetic disorders and consequently fueling the expansion of the nucleic acid and gene therapies sector for neuromuscular conditions.

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Segmentation: How Is The Market Structured Across Key Categories?

The nucleic acid and gene therapies in neuromuscular disorders market covered in this report is segmented –

1) By Disorder: Motor Neuron Diseases, Neuropathies, Neuromuscular Junction Disorders, Myopathies Including Muscular Dystrophies

2) By Therapy: Adeno-Associated Viruses Gene Therapy, Postnatal Gene Therapy

3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgery Centers

Subsegments:

1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS)

2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT), Hereditary Sensory and Autonomic Neuropathy (HSAN), Peripheral Neuropathies

3) By Neuromuscular Junction Disorders: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome (LEMS)

4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD)

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Industry Trends: What Changes Are Reshaping Demand?

Within the realm of nucleic acid and gene therapies for neuromuscular disorders, prominent corporations are actively engaged in the creation of groundbreaking treatments, notably gene therapy, aimed at tackling the fundamental origins of genetically driven neuromuscular ailments through precise gene modification or substitution. Gene therapy involves treating illnesses by introducing, amending, or rectifying genetic material inside a patient’s cells to mend or reinstate compromised genes. A significant development occurred in June 2023 when Sarepta Therapeutics Inc., a biotechnology firm situated in the United States, secured approval from the U.S. Food and Drug Administration for Elevidys, marking the advent of the inaugural gene therapy designed for Duchenne Muscular Dystrophy, specifically targeting ambulatory pediatric individuals aged 4 to 5 years. This therapeutic intervention is administered via a solitary intravenous infusion, streamlining the treatment regimen when contrasted with alternative therapies that might necessitate continuous infusions. ELEVIDYS functions by supplying a gene responsible for encoding a truncated form of dystrophin, referred to as micro-dystrophin, which is crucial for proper muscle functionality. This pioneering strategy confronts the intrinsic genetic flaw by empowering muscle cells to synthesize a functional variant of the dystrophin protein, thus offering the potential to arrest or reverse the advancement of the disease.

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Competitive Landscape And Leading Companies

Major companies operating in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Sanofi S.A, Novartis AG, Biogen Inc, BioMarin Pharmaceuticals Inc, Sarepta Therapeutics Inc, Ionis Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Regenxbio Inc, UniQure N.V, Généthon S.A, Axovant Gene Therapies Inc, PTC Therapeutics Inc, Wave Life Sciences Ltd, CRISPR Therapeutics AG, Editas Medicine Inc, Helixmith Co Ltd, MeiraGTx Ltd, Cure Rare Disease, Beam Therapeutics Inc, Intellia Therapeutics Inc, Prime Medicine Inc, Arcturus Therapeutics Holdings Inc, Takeda Pharmaceutical Company Ltd.

Access The Complete Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Report:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-and-gene-therapies-in-neuromuscular-disorders-global-market-report

Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Geographic Landscape: Which Region Dominates Industry Growth?

North Americawas the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2025. The regions covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Change Between 2026 And 2030?

The nucleic acid and gene therapies in neuromuscular disorders market has experienced significant growth in recent years. It is anticipated to expand from $7.5 billion in 2025 to $8.22 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.7%. Historically, this market’s expansion can be attributed to factors such as limited therapeutic options for NMDs, low awareness regarding gene therapies, the substantial cost of gene therapy development, a shortage of specialized treatment centers, and protracted regulatory approval processes.

The market for nucleic acid and gene therapies in neuromuscular disorders is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $11.76 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.4%. The expansion during the forecast period is propelled by factors such as progress in adeno-associated virus and postnatal gene therapies, increased research and development investments in NMDs, an expanding network of hospitals and specialty clinics providing gene therapies, a growing incidence of neuromuscular disorders, and heightened patient awareness along with advocacy efforts. Key trends characterizing this period encompass a greater acceptance of gene therapy techniques, the accelerated development of nucleic acid therapeutics, an intensified focus on rare neuromuscular disorders, increasing capital directed towards personalized medicine approaches, and the enhanced incorporation of sophisticated diagnostic and monitoring instruments.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21233&type=smp

What Core Drivers Are Transforming The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

The anticipated expansion of the nucleic acid and gene therapies in neuromuscular disorders market is driven by the rising occurrence of genetic disorders. These conditions stem from irregularities in an individual’s DNA, which can be inherited or arise from mutations. Various elements contribute to the rise in genetic disorders, including genetic mutations, environmental factors, shifts in lifestyle, and enhanced diagnostic tools. Nucleic acid and gene therapies address genetic disorders by either correcting or substituting faulty genes within neuromuscular conditions, thereby aiming to restore typical bodily functions. For example, data from May 2024, provided by Cure SMA, a US-based non-profit, indicates that the United States currently has about 9,000 to 9,500 individuals affected by Spinal Muscular Atrophy (SMA). Of this overall population, 37% are living with Type 2 SMA. The estimated incidence rate for this condition is 1 in 15,000 births. Consequently, the expanding occurrence of genetic disorders is a primary factor fueling the development of the nucleic acid and gene therapies in neuromuscular disorders market.

Which Segment Divisions Form The Structure Of The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

The nucleic acid and gene therapies in neuromuscular disorders market covered in this report is segmented –

1) By Disorder: Motor Neuron Diseases, Neuropathies, Neuromuscular Junction Disorders, Myopathies Including Muscular Dystrophies

2) By Therapy: Adeno-Associated Viruses Gene Therapy, Postnatal Gene Therapy

3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgery Centers

Subsegments:

1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS)

2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT), Hereditary Sensory and Autonomic Neuropathy (HSAN), Peripheral Neuropathies

3) By Neuromuscular Junction Disorders: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome (LEMS)

4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD)

Which Trends Are Expected To Shape The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

Companies operating within the nuclear protein in testis midline carcinoma treatment market are concentrating on innovative therapies, particularly combination treatments, to boost their efficacy and improve patient outcomes. Combination therapies are defined as medical approaches that utilize two or more distinct drugs or methods simultaneously to enhance their effectiveness and reduce the development of resistance in combating a disease. As an illustration, in July 2025, Zenith Epigenetics Ltd., a biotechnology company from Canada in the clinical-stage, obtained Fast Track designation approval from the U.S. Food and Drug Administration (FDA) for ZEN 3694 when used in conjunction with abemaciclib. This combination is intended for patients with metastatic or unresectable NUT carcinoma who have already undergone at least one prior chemotherapy regimen. This designation aims to expedite both the development and the regulatory review process for treatments addressing serious conditions where medical needs are currently unmet. These therapeutic approaches, including an oral BET inhibitor, specifically target the oncogenic NUTM1 fusion protein that is a driving force behind NUT carcinoma, while abemaciclib, which functions as a CDK4/6 inhibitor, contributes to inhibiting the proliferation of cancer cells.

Which Organizations Are Operating Within The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

Major companies operating in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Sanofi S.A, Novartis AG, Biogen Inc, BioMarin Pharmaceuticals Inc, Sarepta Therapeutics Inc, Ionis Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Regenxbio Inc, UniQure N.V, Généthon S.A, Axovant Gene Therapies Inc, PTC Therapeutics Inc, Wave Life Sciences Ltd, CRISPR Therapeutics AG, Editas Medicine Inc, Helixmith Co Ltd, MeiraGTx Ltd, Cure Rare Disease, Beam Therapeutics Inc, Intellia Therapeutics Inc, Prime Medicine Inc, Arcturus Therapeutics Holdings Inc, Takeda Pharmaceutical Company Ltd.

Access The Complete Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Report:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-and-gene-therapies-in-neuromuscular-disorders-global-market-report

Which Region Accounts For The Highest Share Of The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2025. The regions covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21233&type=smp

Browse Through More Reports Similar to the Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market 2026, By The Business Research Company

Prostate Cancer Nuclear Medicine Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-nuclear-medicine-diagnostics-global-market-report

Nuclear Medicine Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-global-market-report

Hereditary Cancer Testing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/hereditary-cancer-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Be By 2030 Compared To Its 2026 Market Size?

The market size for nucleic acid and gene therapies in neuromuscular disorders has demonstrated substantial growth in recent years. This market is projected to expand from $7.5 billion in 2025 to $8.22 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.7%. The historical increase in this sector can be attributed to factors like the limited therapeutic options available for nmds, low awareness concerning gene therapies, the high costs involved in gene therapy development, a scarcity of specialized treatment centers, and slow regulatory approval procedures.

The nucleic acid and gene therapies in neuromuscular disorders market size is projected to experience substantial growth in the coming years. It is forecast to grow to $11.76 billion by 2030, expanding at a compound annual growth rate (CAGR) of 9.4%. The anticipated growth over this period is attributable to advancements in adeno-associated virus and postnatal gene therapies, a surge in research and development investments in neuromuscular disorders, an increasing number of hospitals and specialty clinics offering gene therapies, the rising prevalence of neuromuscular disorders, and heightened patient awareness and advocacy initiatives. Key trends during the forecast period involve a growing embrace of gene therapy techniques, expanded development of nucleic acid therapeutics, an amplified focus on rare neuromuscular disorders, increased investment in personalized medicine approaches, and greater integration of advanced diagnostic and monitoring tools.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21233&type=smp

What Primary Drivers Are Shaping The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

A growing incidence of genetic disorders is projected to boost the expansion of the nucleic acid and gene therapies in neuromuscular disorders market in the future. These disorders are conditions resulting from anomalies in an individual’s DNA, which can either be inherited or acquired through mutations. The rise in genetic disorders stems from factors such as genetic mutations, environmental impacts, lifestyle modifications, and enhanced diagnostic capabilities. Nucleic acid and gene therapies offer assistance for genetic disorders by correcting or replacing faulty genes in neuromuscular conditions, aiming to restore normal physiological function. For example, in May 2024, data from Cure SMA, a US-based non-profit organization, indicated that approximately 9,000 to 9,500 individuals in the United States are currently living with Spinal Muscular Atrophy (SMA). Among this total population, 37% have Type 2 SMA, and the condition has an estimated incidence rate of 1 in 15,000 births. Thus, the increasing prevalence of genetic disorders is a key driver for the growth of the nucleic acid and gene therapies in neuromuscular disorders market.

How Are Different Segments Classified In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Segment Analysis?

The nucleic acid and gene therapies in neuromuscular disorders market covered in this report is segmented –

1) By Disorder: Motor Neuron Diseases, Neuropathies, Neuromuscular Junction Disorders, Myopathies Including Muscular Dystrophies

2) By Therapy: Adeno-Associated Viruses Gene Therapy, Postnatal Gene Therapy

3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgery Centers

Subsegments:

1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS)

2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT), Hereditary Sensory and Autonomic Neuropathy (HSAN), Peripheral Neuropathies

3) By Neuromuscular Junction Disorders: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome (LEMS)

4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD)

What Trends Are Affecting The Growth Of The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

Within the nucleic acid and gene therapies in neuromuscular disorders market, major companies are actively developing innovative treatments, such as gene therapy, to target the fundamental causes of genetic neuromuscular conditions through precise gene correction or replacement. Gene therapy involves the medical intervention of introducing, altering, or repairing genetic material within a patient’s cells to correct or replace defective genes. For example, in June 2023, Sarepta Therapeutics Inc., a US-based biotechnology company, secured approval from the U.S. Food and Drug Administration for Elevidys, the inaugural gene therapy for Duchenne Muscular Dystrophy, specifically for ambulatory pediatric patients aged 4 to 5 years. This therapy is administered as a single intravenous infusion, simplifying the treatment process compared to other therapies that might require continuous infusions. ELEVIDYS delivers a gene that codes for a shortened form of dystrophin known as micro-dystrophin, which is crucial for muscle function. This pioneering method addresses the underlying genetic defect by enabling muscle cells to produce a functional version of the dystrophin protein, potentially halting or reversing the progression of the disease.

Who Are The Companies Driving Activity In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

Major companies operating in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Sanofi S.A, Novartis AG, Biogen Inc, BioMarin Pharmaceuticals Inc, Sarepta Therapeutics Inc, Ionis Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Regenxbio Inc, UniQure N.V, Généthon S.A, Axovant Gene Therapies Inc, PTC Therapeutics Inc, Wave Life Sciences Ltd, CRISPR Therapeutics AG, Editas Medicine Inc, Helixmith Co Ltd, MeiraGTx Ltd, Cure Rare Disease, Beam Therapeutics Inc, Intellia Therapeutics Inc, Prime Medicine Inc, Arcturus Therapeutics Holdings Inc, Takeda Pharmaceutical Company Ltd.

Get The Full Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Report:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-and-gene-therapies-in-neuromuscular-disorders-global-market-report

Which Region Leads The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market In Terms Of Market Share?

North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2025. The regions covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-and-gene-therapies-in-neuromuscular-disorders-global-market-report

Browse Through More Reports Similar to the Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market 2026, By The Business Research Company

Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-nuclear-medicine-diagnostics-global-market-report

Nuclear Medicine Market Report

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-global-market-report

Hereditary Cancer Testing Market Report

https://www.thebusinessresearchcompany.com/report/hereditary-cancer-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Over The 2026–2030 Period?

The market size for nucleic acid and gene therapies in neuromuscular disorders has shown strong growth in recent years. It is anticipated to increase from $7.5 billion in 2025 to $8.22 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.7%. Historically, this growth can be attributed to elements such as limited therapeutic options for neuromuscular disorders, low awareness regarding gene therapies, the high expense of developing gene therapies, a scarcity of specialized treatment centers, and slow regulatory approval processes.

The nucleic acid and gene therapies in neuromuscular disorders market is anticipated to observe significant growth over the next few years. It is projected to expand to $11.76 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.4%. This growth in the forecast period can be attributed to advancements in adeno-associated virus and postnatal gene therapies, increased research and development investments in neuromuscular disorders (NMDs), a rising number of hospitals and specialty clinics offering gene therapies, the growing prevalence of neuromuscular disorders, and increasing patient awareness and advocacy initiatives. Major trends for the forecast period include the rising adoption of gene therapy techniques, the increasing development of nucleic acid therapeutics, a growing focus on rare neuromuscular disorders, rising investment in personalized medicine approaches, and the increasing integration of advanced diagnostic and monitoring tools.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21233&type=smp

What Underlying Factors Are Accelerating The Growth Of The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

The escalating occurrence of genetic conditions is projected to drive the expansion of the nucleic acid and gene therapies in neuromuscular disorders market in the future. These disorders are illnesses arising from irregularities in a person’s DNA, which can be inherited or develop from mutations. The rise in genetic disorders stems from elements like genetic alterations, environmental factors, shifts in lifestyle, and enhanced diagnostic tools. Nucleic acid and gene therapies address genetic disorders by rectifying or substituting faulty genes within neuromuscular conditions, aiming to reinstate typical functionality. As an illustration, in May 2024, data from Cure SMA, a US-based non-profit organization, indicated that around 9,000 to 9,500 people in the United States are currently affected by Spinal Muscular Atrophy (SMA). Of this total, 37% suffer from Type 2 SMA, with the condition’s estimated occurrence being 1 in 15,000 births. Consequently, the growing frequency of genetic disorders is propelling the advancement of the nucleic acid and gene therapies in neuromuscular disorders market.

How Is The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Segmented Across Key Categories?

The nucleic acid and gene therapies in neuromuscular disorders market covered in this report is segmented –

1) By Disorder: Motor Neuron Diseases, Neuropathies, Neuromuscular Junction Disorders, Myopathies Including Muscular Dystrophies

2) By Therapy: Adeno-Associated Viruses Gene Therapy, Postnatal Gene Therapy

3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgery Centers

Subsegments:

1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS)

2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT), Hereditary Sensory and Autonomic Neuropathy (HSAN), Peripheral Neuropathies

3) By Neuromuscular Junction Disorders: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome (LEMS)

4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD)

Which Upcoming Trends Are Expected To Influence The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

Leading companies within the nucleic acid and gene therapies in neuromuscular disorders market are dedicated to creating ground-breaking treatments, including gene therapy, to tackle the fundamental causes of genetic neuromuscular conditions via precise gene correction or substitution. Gene therapy involves managing diseases by inserting, modifying, or mending genetic material inside a patient’s cells to rectify or substitute faulty genes. An example of this is the approval granted in June 2023 by the U.S. Food and Drug Administration to Sarepta Therapeutics Inc., a US-based biotechnology company, for Elevidys. This marked the initial gene therapy designed for Duchenne Muscular Dystrophy, specifically targeting ambulatory pediatric patients aged 4 to 5 years. This treatment is given as a single intravenous infusion, streamlining the therapeutic procedure when contrasted with other treatments that might necessitate continuous infusions. ELEVIDYS introduces a gene responsible for producing micro-dystrophin, a shorter variant of dystrophin crucial for proper muscle function. This pioneering method tackles the foundational genetic flaw by allowing muscle cells to generate a working form of the dystrophin protein, potentially arresting or reversing the disease’s advancement.

Who Are The Dominant Players Shaping The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Landscape?

Major companies operating in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Sanofi S.A, Novartis AG, Biogen Inc, BioMarin Pharmaceuticals Inc, Sarepta Therapeutics Inc, Ionis Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Regenxbio Inc, UniQure N.V, Généthon S.A, Axovant Gene Therapies Inc, PTC Therapeutics Inc, Wave Life Sciences Ltd, CRISPR Therapeutics AG, Editas Medicine Inc, Helixmith Co Ltd, MeiraGTx Ltd, Cure Rare Disease, Beam Therapeutics Inc, Intellia Therapeutics Inc, Prime Medicine Inc, Arcturus Therapeutics Holdings Inc, Takeda Pharmaceutical Company Ltd.

Read the full nucleic acid and gene therapies in neuromuscular disorders market report here:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-and-gene-therapies-in-neuromuscular-disorders-global-market-report

Which Region Is Projected To Dominate The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market During The Forecast Period?

North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2025. The regions covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21233&type=smp

Browse Through More Reports Similar to the Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market 2026, By The Business Research Company

Prostate Cancer Nuclear Medicine Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/prostate-cancer-nuclear-medicine-diagnostics-global-market-report

Nuclear Medicine Global Market Report

https://www.thebusinessresearchcompany.com/report/nuclear-medicine-global-market-report

Hereditary Cancer Testing Global Market Report

https://www.thebusinessresearchcompany.com/report/hereditary-cancer-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the nucleic acid and gene therapies in neuromuscular disorders market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

The nucleic acid and gene therapies in neuromuscular disorders market has experienced robust growth in size over recent years. It is projected to expand from $7.5 billion in 2025 to $8.22 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.7%. Historically, the market’s growth can be attributed to several factors including limited therapeutic options for nmds, low awareness of gene therapies, the significant cost involved in gene therapy development, a shortage of specialized treatment centers, and slow regulatory approvals.

The market for nucleic acid and gene therapies in neuromuscular disorders is projected to experience substantial growth in the upcoming years, expanding to $11.76 billion by 2030 with a compound annual growth rate (CAGR) of 9.4%. This anticipated expansion during the forecast period is primarily fueled by advancements in adeno-associated virus and postnatal gene therapies, increased research and development investments in NMDs, a rising number of hospitals and specialty clinics providing gene therapies, the growing incidence of neuromuscular disorders, and enhanced patient awareness and advocacy programs. Key trends expected over this period involve the increasing adoption of gene therapy methodologies, intensified development of nucleic acid therapeutics, a sharpened focus on rare neuromuscular disorders, greater investment in personalized medicine strategies, and the broader integration of advanced diagnostic and monitoring instruments.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21233&type=smp

What Drivers Are Supporting Technological Adoption In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

The anticipated expansion of the nucleic acid and gene therapies in neuromuscular disorders market is linked to the rising occurrence of genetic disorders. These disorders are defined as conditions stemming from DNA irregularities within a person, which can be either inherited or triggered by mutations. The surge in genetic disorders can be attributed to several elements, including genetic mutations, environmental factors, shifts in lifestyle, and enhanced diagnostic tools. Nucleic acid and gene therapies address genetic disorders by either rectifying or substituting faulty genes in neuromuscular conditions, thereby aiding in the restoration of typical physiological function. For example, data from May 2024, provided by Cure SMA, a US-based non-profit, indicates that the United States has approximately 9,000 to 9,500 individuals presently affected by Spinal Muscular Atrophy (SMA). Of this total population, 37% are diagnosed with Type 2 SMA. The estimated incidence for this condition stands at 1 in 15,000 births. Consequently, the growing occurrence of genetic disorders is propelling the expansion of the nucleic acid and gene therapies in neuromuscular disorders market.

Which Segments Are Contributing To The Growth Of The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

The nucleic acid and gene therapies in neuromuscular disorders market covered in this report is segmented –

1) By Disorder: Motor Neuron Diseases, Neuropathies, Neuromuscular Junction Disorders, Myopathies Including Muscular Dystrophies

2) By Therapy: Adeno-Associated Viruses Gene Therapy, Postnatal Gene Therapy

3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgery Centers

Subsegments:

1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS)

2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT), Hereditary Sensory and Autonomic Neuropathy (HSAN), Peripheral Neuropathies

3) By Neuromuscular Junction Disorders: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome (LEMS)

4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD)

What Trends Are Reshaping The Dynamics Of The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

Leading companies active in the nucleic acid and gene therapies in neuromuscular disorders market are concentrating on developing innovative treatments, such as gene therapy, to tackle the fundamental causes of genetic neuromuscular conditions through targeted gene correction or replacement. Gene therapy involves managing diseases by introducing, modifying, or repairing genetic material within a patient’s cells to correct or substitute defective genes. As an example, in June 2023, Sarepta Therapeutics Inc., a US-based biotechnology company, obtained approval from the U.S. Food and Drug Administration for Elevidys, which is the first gene therapy for Duchenne Muscular Dystrophy, specifically for ambulatory pediatric patients aged 4 to 5 years. This therapy is administered as a single intravenous infusion, thereby streamlining the treatment process compared to other therapies that might necessitate ongoing infusions. ELEVIDYS delivers a gene that codes for a shortened form of dystrophin known as micro-dystrophin, a substance vital for muscle function. This pioneering method addresses the underlying genetic flaw by enabling muscle cells to produce a functional version of the dystrophin protein, potentially halting or even reversing disease progression.

Who Are The Core Companies Influencing Trends In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

Major companies operating in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Sanofi S.A, Novartis AG, Biogen Inc, BioMarin Pharmaceuticals Inc, Sarepta Therapeutics Inc, Ionis Pharmaceuticals Inc, Ultragenyx Pharmaceutical Inc, Regenxbio Inc, UniQure N.V, Généthon S.A, Axovant Gene Therapies Inc, PTC Therapeutics Inc, Wave Life Sciences Ltd, CRISPR Therapeutics AG, Editas Medicine Inc, Helixmith Co Ltd, MeiraGTx Ltd, Cure Rare Disease, Beam Therapeutics Inc, Intellia Therapeutics Inc, Prime Medicine Inc, Arcturus Therapeutics Holdings Inc, Takeda Pharmaceutical Company Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-and-gene-therapies-in-neuromuscular-disorders-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?

North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2025. The regions covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21233&type=smp

Browse Through More Reports Similar to the Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market 2026, By The Business Research Company

Ribose Nucleic Acid Rna Based Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/ribose-nucleic-acid-rna-based-therapeutics-global-market-report

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Oligonucleotides Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model